Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942189 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2AALDH1A1APEX1LMNA | |
| SCHEMBL10107716 | 0.79 | APEX1 (0.66) | SMN1; SMN2KMT2AALDH1A1APEX1LMNA | |
| SCHEMBL21296258 | 0.78 | HPGD (0.69) | SMN1; SMN2KMT2AALDH1A1APEX1LMNA | |
| SCHEMBL2314409 | 0.77 | GALR3 (0.65) | SMN1; SMN2ALDH1A1LMNAL3MBTL1RECQL | |
| SCHEMBL15300449 | 0.77 | KMT2A (0.53) | SMN1; SMN2KMT2AALDH1A1APEX1NR1H4 | |
| SCHEMBL16651061 | 0.77 | HPGD (0.70) | SMN1; SMN2KMT2AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL11469323 | 0.77 | POLB (0.67) | ALDH1A1APEX1L3MBTL1NR1H4POLB | |
| SCHEMBL16135593 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AALDH1A1APEX1LMNA | |
| SCHEMBL2683893 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AALDH1A1APEX1LMNA | |
| SCHEMBL6168711 | 0.75 | KMT2A (0.43) | KMT2AL3MBTL1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| EP-2349262-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | SMN1; SMN2 2353/4885KMT2A 646/4885ALDH1A1 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.